Skip to content
Elections Simplified

Samir Witta

Unaffiliated · CO

Official website

Cancer doctor who founded Mountain Blue Cancer Care and holds a Ph.D. with research experience at the National Institutes of Health. His priorities are lower drug prices and more affordable health coverage, and anti-corruption rules for Congress.

Where Samir Witta stands, based on their records

Supports

Environment and Public Health (5 records)

Campaign Finance Information — United States Representative, Congressional District 6

Campaign Finance Information

Data last updated September 21, 2026

Raised
$100
Spent
$59,159
Cash on hand
-$58,959
Debts
$66,173

Spent can be higher than Raised because campaigns can also use money that Raised does not count, like loans or funds from earlier years.

PAC money by interest

No PAC donations reported.

Donations sent through groups

No donations sent through groups reported.

Source: FEC · 2026 cycle

Track record

Track record — Environment and Public Health

Environment and Public Health · 5 support

  • Coauthored a published randomized phase II trial of erlotinib with or without entinostat for advanced lung cancer.

    April 16, 2012Supports Environment and Public Health

    Source: pubmed.ncbi.nlm.nih.gov · researched September 19, 2026

  • Was named as an inventor on a published U.S. patent application for using SAHA and erlotinib to treat cancer.

    September 11, 2008Supports Environment and Public Health

    Source: patents.google.com · researched September 19, 2026

  • Served as a principal investigator on a registered randomized study of erlotinib with or without entinostat for advanced lung cancer.

    January 28, 2008Supports Environment and Public Health

    Source: clinicaltrials.gov · researched September 19, 2026

  • Led a published study linking restored E-cadherin expression with greater sensitivity to lung-cancer EGFR inhibitors.

    January 15, 2006Supports Environment and Public Health

    Source: pubmed.ncbi.nlm.nih.gov · researched September 19, 2026

  • Coauthored a published phase I study of exisulind and docetaxel in patients with advanced solid tumors.

    November 1, 2004Supports Environment and Public Health

    Source: pubmed.ncbi.nlm.nih.gov · researched September 19, 2026

Race Samir Witta is in:

Profile last researched September 19, 2026.